Cancer Clinical Trials
This is a current listing of active clinical trials at the Aspirus Regional Cancer Center. From this list you can select a specific cancer that you are interested in (for example, breast or colon cancer) and then review the clinical trials that are active at the Aspirus Regional Cancer Center for that specific disease.
Prostate Cancer - Advanced Hormone Refractory
Trial Name: Name of Trial: A Phase III Trial of Short Term Androgen Deprivation with Pelvic Lymph Node or Prostate Bed Only Radiotherapy (SPPORT) in Prostate Cancer Patients with a Rising PSA After Radical Prostatectomy.
Protocol ID: RTOG 0534
· Adenocarcinoma of the prostate treated primarily with radical prostatectomy, pathologically proven to be lymph node negative by pelvic lymphadenectomy or lymph node status pathologically unknown.
· Age > 18
· Must be required laboratory values
· Prior pelvic radiotherapy
· Prior invasive malignancy (except non-melanomatous skin cancer) unless disease free for a minimum of 5 years (for example, carcinoma in situ of the oral cavity is permissible).
· History of inflammatory bowel disease
· History of hepatitis B or C
Prior allergic reaction to the study drug(s) involved in this protocol
Enrollment: Enrollment: · About 1, 764 people will take part in this study.
If you agree to take part in this study, there may or may not be direct medical benefit to you. It is not know whether the combination of radiation to the prostate bed plus hormone therapy is better than radiation to the prostate bed alone. Also, it is not know whether radiation to the pelvic lymph nodes and prostate bed plus hormone therapy is better than radiation to the prostate bed only combined with hormone therapy. We do know that the information from this study will help researchers learn more about how best to treat men who have a rising PSA after surgery to remove their prostate. This information could help future cancer patients.
These clinical trial overviews are intended to provide a brief overview of the clinical trial. To help determine whether the trial is appropriate for you, the major eligibility criteria are listed above. To obtain more information on the eligibility and the treatment plan, please contact our Oncology Clinical Research Coordinator, Beth Knetter at 715-847-2353 or 1-800-283-2881, ext.72353.
Created: Jul 31, 2009
Updated: Jul 19, 2013